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Identification of cancer related genes and 
proteins that can serve as diagnostic, 
prognostic, and/or therapeutic biomarkers 
is essential to improve targeted manage-
ment of cancer. Because of the diversity 
of molecular pathways by which cancers 
arise, even within cancers of similar cellu-
lar origin, many markers, or combinations 
of markers, will likely be required to accu-
rately profile each case of cancer for an 
accurate diagnosis and effective treatment. 
Thus, a great deal of scientific research 
is currently being devoted to exploring 
the relationships between putative can-
cer biomarkers and therapeutic response. 
Recently, CHFR (CHeckpoint with 
Forkhead-associated domain and Ring 
finger), a cell cycle checkpoint regulator, 
has been attracting increased attention 
as a potential predictor of chemotherapy 
response. Decreased CHFR expression 
has been observed in a wide array of can-
cer types ranging from breast to urogeni-
tal tumors.1 Most often, reduced CHFR 
expression results from increased methyla-
tion of its gene promoter1 but some cancers 
demonstrate CHFR loss without evidence 
of promoter hypermethylation.2 Loss of 
CHFR expression has been shown to con-
fer cellular characteristics associated with 
cancer, such as an accelerated growth rate, 
enhanced cell motility, increased invasive-
ness and higher rates of aneuploidy,1,3,4 
which likely result, at least in part, from 
a failed checkpoint arrest in cells that may 
already lack normal apoptotic mecha-
nisms. Accordingly, CHFR knockout 
mice have increased incidence of sponta-
neous and DMBA (7,12-dimethylbenz[α]
anthracene)-induced tumors.4
Connections between CHFR, the cell cycle and chemosensitivity
Are they critical in cancer?
Jennifer A. Keller,1 Ayse Elif Erson-Bensan3 and Elizabeth M. Petty2,*
1Department of Cell and Developmental Biology; 2Departments of Human Genetics and Internal Medicine; University of Michigan; Ann Arbor, MI USA; 
3Department of Biological Sciences; Middle East Technical University; Ankara, Turkey
CHFR is an E3 ubiquitin ligase pro-
tein responsible for an early mitotic check-
point.1,5 CHFR was first identified as a 
checkpoint protein essential for its role in 
causing a delay in chromosome conden-
sation due to microtubule stress before 
entry into mitosis.5 This work established 
CHFR as a component of the so-called 
“antephase” checkpoint which monitors 
microtubule-dependent events between 
prophase and metaphase.5 More recent 
studies have also implicated CHFR in 
the spindle assembly checkpoint between 
metaphase and anaphase,4,6,7 which can 
also be triggered by microtubule targeting 
drugs. Given this, it is hypothesized that 
CHFR functions in two distinct cellular 
checkpoints during mitosis where CHFR 
functions to halt the cell cycle in response 
to microtubule damage or spindle defects, 
ensuring proper chromosome segregation 
and cell division.1,5 In addition, CHFR 
activity has been implicated in processes 
leading to metastasis and angiogen-
esis (Fig. 1).8,9 Reduction of endogenous 
CHFR in cell lines resulted in onset of 
tumor-like phenotypes such as increased 
mitotic index, growth rate, invasiveness, 
aneuploidy, motility and soft agar colony 
formation.7 In cancer cell lines that express 
little or no CHFR, restoration of CHFR 
expression reduced phenotypes including 
mitotic index, invasiveness, motility and 
growth rate.7
CHFR’s dual checkpoint function may 
be carried out, at least in some cases, by 
CHFR-mediated ubiquitination/degrada-
tion of AurA (Aurora A kinase), a protein 
that drives mitotic progression,10 although 
this mechanism has been questioned.11 
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head and neck squamous cell carcino-
mas,18 but is found in all stages in gastric 
and esophageal cancers.19 Additionally, 
CHFR loss has been observed in breast, 
lung, colorectal, ovarian and cervical can-
cers and leukemias.1 Clearly, CHFR loss 
represents an important step in the pro-
gression of several cancers, and therefore 
could be extremely useful as a prognostic 
and therapeutic biomarker.
While decreased and/or lost CHFR 
expression is implicated in cancer pro-
gression, it also represents a promising 
biomarker for cancer treatments. The sta-
tus of CHFR, as well as related proteins, 
in a given tumor may be informative for 
microtubule targeting drug therapies. 
Cell lines in which CHFR expression 
has been inhibited show reduced survival 
and increased apoptosis when treated 
with microtubule-targeting drugs.7,20,21 
Therefore, CHFR represents an impor-
tant marker for sensitivity to microtubule-
specific chemotherapeutics.
One of the challenges in treating can-
cers is that many chemotherapeutics are 
but continue mitosis resulting in mitotic 
defects such as failed nuclear separation, lag-
ging chromosomes and failed cytokinesis.4,5
Entry into mitosis is thought to be con-
trolled by CHFR specifically by regulat-
ing Cyclin B1/CDC2 activity.5,11 There 
is also evidence that CHFR can also 
ubiquitinate PLK1 (polo-like kinase 1) 
and target it for degradation.14 PLK1 is 
known to promote mitotic entry through 
phosphorylation of its targets CDC25C 
and CDK1/Cyclin B.15 Overexpression 
of PLK1 has been associated with many 
tumor types, including NSCLCs and cor-
relates with tumor progression.16 CHFR 
promoter hypermethylation has been 
observed in many cancer types, including 
lung cancers and CHFR loss is associated 
with increased malignant potential and 
poor outcomes.1 Therefore, CHFR is an 
interesting prognostic marker and chemo-
therapeutic target in cancer. CHFR loss 
has been implicated in the progression of 
a wide array of cancer types.1 CHFR loss 
has been associated with advanced tumor 
stage in hepatocellular carcinomas17 and 
Aurora A is critical for centrosome dupli-
cation and is also involved in the spindle 
assembly checkpoint.10 Loss of AurA 
inhibits proper bipolar spindle formation 
and results in mitotic arrest, while over-
expression of AurA has been shown to 
induce multipolar spindle formation and 
is linked to oncogenic phenotypes such as 
aneuploidy.12 Similar phenotypes are seen 
when CHFR expression is reduced, which 
increases AurA levels in the cell.4,7
MAD2 (Mitotic Arrest Deficient 2), 
a protein that is recruited to unattached 
kinetochores to act in the spindle-assembly 
checkpoint during mitosis, has recently 
been shown to bind to CHFR protein.7,13 
Loss of CHFR results in the mislocaliza-
tion of MAD2 and BUBR1, both of which 
bind to kinetochores and are critical for 
the spindle assembly checkpoint.7 CHFR 
reduction also disrupts the CDC20/MAD2 
complex, which frees CDC20 to activate 
the anaphase-promoting complex and leads 
to progression through mitosis.7 Cells with 
reduced CHFR expression do not delay 
metaphase in response to spindle defects, 
Figure 1. The role of CHFr in the cell cycle and neoplastic processes. CHFr loss has been implicated in several cancer progression-related phenotypes. 
CHFr has been shown to target HDaC1 for degradation, linking CHFr loss to metastasis.8 CHFr expression in some cancer lines reduced NFkappaB and 
reduced angiogenesis in a xenograft model.9 In addition, several downstream effectors of CHFr involved in mitotic checkpoint processes have been 
identified. PLK1, aurora a and KIF22 are ubiquitination targets of CHFr,4,6,14 maD2 has been shown to interact with CHFr,7 and CyclinB1/CDC2 appears 
to be regulated by CHFr expression.5,11 Loss of the antephase and spindle checkpoints results in more rapid growth and increased aneuploidy when 
CHFr is lost.
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The strong correlation between smok-
ing status and CHFR methylation pre-
sented by Takeshita et al. coupled with 
previous data that EGFR mutation and 
CHFR methylation are mutually exclu-
sive,24 raises the question: Can smok-
ing status and EGFR mutation status be 
effectively combined to predict paclitaxel 
response in NSCLCs without measure-
ment of CHFR methylation status? In 
addition, other related genes, such as 
SIRT2, a tubulin deacetylase that is 
involved in the same antephase checkpoint 
processes as CHFR and is lost in gliomas25 
or PLK1, which is lost in many cancer 
types,14 may be predictive of the chemo-
therapeutic response to paclitaxel simi-
lar to CHFR methylation status. Clearly, 
significant work is still needed to identify 
additional genetic markers for predicting 
chemotherapeutic response to paclitaxel in 
order to effectively treat each cancer case.
References
1. Privette LM, Petty EM. CHFR: A novel mitotic 
checkpoint protein and regulator of tumorigenesis. 
Transl Oncol 2008; 1:57-64.
2. Erson AE, Petty EM. CHFR-associated early G
2
/M 
checkpoint defects in breast cancer cells. Mol 
Carcinog 2004; 39:26-33.
3. Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty 
EM. Altered expression of the early mitotic check-
point protein, CHFR, in breast cancers: implications 
for tumor suppression. Cancer Res 2007; 67:6064-74.
4. Yu X, Minter-Dykhouse K, Malureanu L, Zhao 
WM, Zhang D, Merkle CJ, et al. CHFR is required 
for tumor suppression and Aurora A regulation. Nat 
Genet 2005; 37:401-6.
5. Scolnick DM, Halazonetis TD. CHFR defines a 
mitotic stress checkpoint that delays entry into meta-
phase. Nature 2000; 406:430-5.
6. Maddika S, Sy SM, Chen J. Functional interaction 
between Chfr and Kif22 controls genomic stability. J 
Biol Chem 2009; 284:12998-3003.
7. Privette LM, Weier JF, Nguyen HN, Yu X, Petty 
EM. Loss of CHFR in human mammary epithe-
lial cells causes genomic instability by disrupting 
the mitotic spindle assembly checkpoint. Neoplasia 
2008; 10:643-52.
8. Oh YM, Kwon YE, Kim JM, Bae SJ, Lee BK, Yoo 
SJ, et al. Chfr is linked to tumour metastasis through 
the downregulation of HDAC1. Nat Cell Biol 2009; 
11:295-302.
9. Kashima L, Toyota M, Mita H, Suzuki H, Idogawa 
M, Ogi K, et al. CHFR, a potential tumor suppressor, 
downregulates interleukin-8 through the inhibition 
of NFkappaB. Oncogene 2009; 28:2643-53.
effective in only a subset of patients. In 
order to provide the best outcomes, it is 
important to have methods to determine 
the best course of treatment for each 
individual case. Because cancers arise 
from a variety of genetic changes, treat-
ment choices may be optimized based on 
the genetic features of the cancer cells. 
This represents a powerful tool by which 
physicians can choose the most effective 
treatment for their patients. In this issue, 
a strong correlation between CHFR loss 
and sensitivity to microtubule drugs such 
as paclitaxel has been demonstrated in 
NSCLC,22 suggesting that CHFR pro-
moter methylation could be used as a pre-
dictive marker of drug response. However, 
work by Yoshida et al. suggests that, in 
advanced and recurrent gastric cancer, 
CHFR promoter methylation does not 
predict response to paclitaxel.23 This may 
indicate that gastric cancers often contain 
other mutations that counteract the pacli-
taxel sensitivity conferred by CHFR loss. 
Thus, additional markers may be required 
to determine proper drug response. In the 
current issue of Cancer Biology & Therapy, 
Takeshita et al. present evidence that the 
combination of CHFR methylation status, 
EGFR mutation status and patient smok-
ing habit can more effectively predict 
tumor response to paclitaxel treatment in 
NSCLC.22
CHFR promoter methylation alone 
may not be informative enough as a pre-
dictor of chemoresponsiveness in all can-
cers. As discussed by Takeshita et al. the 
invasiveness of the procedure necessary to 
determine CHFR promoter methylation 
status in lung cancers (and likely other 
solid tumors as well) make CHFR-based 
predictions less than ideal in NSCLC.22 
This indicates the importance of finding 
alternate indicators for drug response. 
Takeshita et al. observed a significant 
correlation between wild-type EGFR and 
paclitaxel response,22 which might also be 
useful in the absence of CHFR methyla-
tion status data.
